Phlox Therapeutics
Phlox Therapeutics uses smart RNA designs to target multiple Lamin A/C mutations, offering therapies for rare genetic cardiomyopathies. Their constructs, developed by the group of Amsterdam UMC Professor Yigal Pinto, show promising therapeutic effects in patient-derived cardiomyocytes. Phlox Therapeutics aims to expand their technology to other treatment-resistant cardiomyopathies.
PacingCure
PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.
Haermonics
Innovating post-surgery care, Haermonics develops a device to flush and clean the pericardial space, preventing blood-related complications after open-heart surgery. Their technology reduces the risk of blood clots and subsequent operations. The company is dedicated to improving surgical outcomes through advanced medical devices.
